Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Clinical trial NCT05727904 · RECRUITING
Trial details
- NCT number
- NCT05727904
- Sponsor
- Iovance Biotherapeutics, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-30
- Primary completion
- 2028-03-01
- Enrollment
- 670
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.